-
Association Between Guideline Concordant Treatment and Healthcare Resource Utilization and Clinical Outcomes Among Older Adults Newly Diagnosed with Stage III - IV Melanoma
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness of Intravenous Ferric Carboxy Maltose Versus Iron Sucrose to Treat Anemia in Pregnancy in Indian Context
Mar 10, 2025, 14:00 PM -
Staffing Resource Use: A Cost Impact Model for the Utilization and Implementation of Medications for Opioid Use Disorder Within US Jails And Prisons
Mar 10, 2025, 14:00 PM -
Co-Design of a Discrete Choice Experiment for Revascularization Decisions in Complex Coronary Heart Disease: Importance of Patient Perspectives
Mar 10, 2025, 14:00 PM -
Empowering Patients in Observational Research: Leveraging Data Insights for Sustained Engagement and Innovation
Mar 10, 2025, 14:00 PM -
Health Utility Values of Canadian Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer
Mar 10, 2025, 14:00 PM -
Impact of Emicizumab on Quality of Life and Clinical Outcomes in Patients with Hemophilia A in Guatemala
Mar 10, 2025, 14:00 PM -
Inequities in Access to Oncology Drugs in Brazil - the Case of Public and Private Healthcare Systems
Mar 10, 2025, 14:00 PM -
Development of a Conceptual Model of the Patient Experience with Idiopathic Hypersomnia: Patient Interviews from a Clinical Trial (NCT05156047)
Mar 10, 2025, 14:00 PM -
Costs of Type 2 Diabetes Mellitus and Obesity in Colombian Caribbean Poor Population: A Top-Down Approach from a Cardiovascular Risk Cohort, 2020-2022
Mar 10, 2025, 14:00 PM -
Is Bayesian Statistics an Emerging Way for Extrapolating Survival in Cost-Effectiveness Analysis: A Systematic Review
Mar 10, 2025, 14:00 PM -
Do Breakthrough Therapies Demonstrate Breakthrough Value to Payers? An Evaluation of US Hemophilia B Gene Therapy Access Policies
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness of Pegfilgrastim Versus 5-day Filgrastim in Early Breast Cancer Patients Undergoing Neoadjuvant and Adjuvant Chemotherapy: A Trial-Based Economic Evaluation
Mar 10, 2025, 14:00 PM -
The Costs Associated with Healthcare Resource Use and Work Productivity for Care Partners of Multiple Myeloma Patients in the United States and Europe
Mar 10, 2025, 14:00 PM -
Comparing the Social and Private Value Created by Pembrolizumab 2014-2022
Mar 10, 2025, 14:00 PM -
Broadening the Evidence Base: Incorporating Environmental Considerations Into HTAs
Mar 10, 2025, 14:00 PM -
Role of Relative Dose Intensity in Health Economic Evaluations: A Review of National Institute for Health and Care Excellence Technology Appraisals of Treatments in Solid Tumors
Mar 10, 2025, 14:00 PM -
Machine Learning for Predictive Modeling of Hospitalization Risk in Myasthenia Gravis Patients Using the MGFA Global Patient Registry: Addressing Imbalanced Data in Real-World Evidence Scenarios
Mar 10, 2025, 14:00 PM -
Impact of Adverse Event Definitions on Real-World Detection of Oncology Immune-Related Adverse Events
Mar 10, 2025, 14:00 PM -
Economic and Health Care Resource Utilization (HCRU) Burden of Acute Myocardial Infarction (AMI) With or Without Systemic Inflammation in US Hospitals: A Real-World Study
Mar 10, 2025, 14:00 PM
